Infosys Limited (NYSE:INFY) shares are up during Thursday’s premarket session. On Wednesday, the company disclosed two acquisitions – Stratus and Optimum Healthcare IT.
Optimum Healthcare IT Acquisition
Infosys plans to acquire Optimum Healthcare IT for around $465 million, including an upfront payment and earnouts.
The company expects the deal to conclude in the first quarter of fiscal year 2027, pending regulatory and other closing conditions.
With this deal, Infosys expects to offer AI-powered cloud and digital transformation for healthcare providers.
Salil Parekh, Chief Executive Officer, Infosys, added, “By bringing together Optimum’s provider experience with Infosys Topaz and Infosys Cobalt, we are positioned to create a differentiated value proposition for healthcare providers – accelerating end–to–end cloud, data, and digital transformation at scale.”
Stratus Buyout
Also, the company bought Stratus, which is a technology solutions provider for the property and casualty insurance industry. The acquisition price is up to $95 million, including upfront payment and earnouts.
The company expects the acquisition to close in the first quarter of FY 2027, subject to closing conditions.
The acquisition is anticipated to strengthen Infosys’ leadership in the insurance sector, leveraging Stratus’ expertise in Guidewire Software and its capabilities in data transformation for global P&C insurers.
The integration of Stratus’ technology consulting with Infosys’ existing offerings is expected to enhance their ability to support insurers in core modernization and cloud adoption.
This acquisition aligns with the growing demand for AI solutions in the insurance industry, particularly in areas like claims automation and risk modeling.
Kannan Amaresh, SVP & Head of Insurance, Infosys, said, “AI is fundamentally transforming the global insurance industry, strengthening decision-making across underwriting, claims, and fraud detection, while making systems intelligent and significantly improving operational efficiency. The P&C segment is leading AI adoption in the insurance sector, driven by the need for claims automation, advanced underwriting, and sophisticated risk modeling amid claim volumes and elevated risks exposure. Infosys is unlocking AI value for P&C insurers through digital and data-led transformation.”
Infosys Earnings & Analyst Outlook
Infosys is slated to provide its next financial update on Apr. 16, 2026 (estimated).
- EPS Estimate: 21 cents (Up from 20 cents)
- Revenue Estimate: $275.23 billion (Up from $4.73 billion)
- Valuation: P/E of 17.1x (Indicates fair valuation)
Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $19.86. Recent analyst moves include:
- Stifel: Hold (Lowers Target to $17.00) (Feb. 18)
- TD Cowen: Hold (Raises Target to $18.00) (Jan. 15)
- BMO Capital: Market Perform (Raises Target to $20.00) (Jan. 15)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Infosys Limited American Depositary Shares, highlighting its strengths and weaknesses compared to the broader market:
- Value: 60.96 — Trading at a fair valuation relative to peers.
- Growth: 31.66 — Indicates moderate growth potential.
- Quality: 70.01 — Reflects a strong balance sheet.
- Momentum: 7.99 — Stock is underperforming the broader market.
The Verdict: Infosys Benzinga Edge signal reveals a balanced scorecard with strong quality metrics but weak momentum, suggesting a cautious approach for investors looking for growth. The recent acquisition positions the company well for future growth, but current momentum indicators reflect challenges in the short term.
Top ETF Exposure
- First Trust NASDAQ Cybersecurity ETF (NASDAQ:CIBR): 7.97% Weight
- Dimensional Emerging Markets ex China Core Equity ETF (NYSE:DEXC): 0.80% Weight
- Global X India Active ETF (NYSE:NDIA): 4.66% Weight
Significance: Because INFY carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
INFY Price Action: Infosys shares were up 0.23% at $13.20 during premarket trading on Thursday. The stock is near its 52-week low of $12.57, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment